Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 170 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Selpercatinib Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC MOST POPULAR Health of Gut Microbes May Affect Survival after Stem Cell Transplant March 25, 2020 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Merging the Histologic and Molecular Data Into an Integrated Score Significantly... October 11, 2021 Load more HOT NEWS Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported... Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed... High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint... Man Becomes Nervous About How Cop Acts During Ticket, Then He...
